Synopsis
Synopsis
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cefuroxime
2. Cephuroxime
3. Ketocef
4. Zinacef
1. Sodium Cefuroxime
2. Zinacef
3. Cefuroxime Sodium Salt
4. Biociclin
5. 56238-63-2
6. Anaptivan
7. Kefurox
8. Cefuroxime (sodium)
9. Cefumax
10. Cefurex
11. Medoxim
12. Kesint
13. Chebi:3517
14. R8a7m9my61
15. Colifossim
16. Sodium (6r,7r)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(z)-(o-methyloxime), Carbamate (ester)
17. Spectrazolr
18. Bioxima
19. Cefofix
20. Curoxim
21. Curoxima
22. Curoxime
23. Furoxil
24. Ketocef
25. Ultroxim
26. Cefuroxim Hexal
27. Cefuroxim Lilly
28. Cefuroxima Fabra
29. Cefuroxim Aj
30. Cefuroxim Mn
31. Cefuroxim Curasan
32. Cefuroxima Richet
33. Cetroxil [inj.]
34. Cefuroxim Fresenius
35. Cefuroxim Genericsn
36. Froxal [inj.]
37. Sharox [inj.]
38. Zinnat [inj.]
39. Cetroxil
40. Froxal
41. Cefuroxim Norcox
42. Cefuroxim Norcox [inj.]
43. Cefuroxime Na
44. Kefurox In Plastic Container
45. Zinacef In Plastic Container
46. Zinacef (tn)
47. Einecs 260-073-1
48. Cefuroxime And Dextrose In Duplex Container
49. Unii-r8a7m9my61
50. Mls000069576
51. Cefuroxime Sodium [usp:ban:jan]
52. Cefuroxime For Injection And Dextrose For Injection In Duplex Container
53. Sodium;(6r,7r)-3-(carbamoyloxymethyl)-7-[[(2z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
54. Ks-1040
55. Smr000058808
56. Mls001332625
57. Mls001332626
58. Sodium (6r-(6alpha,7beta(z)))-3-(((aminocarbonyl)oxy)methyl)-7-(2-furyl(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate
59. Cefuroxime Sodium (jan/usp)
60. Schembl719536
61. Cefuroxime Sodium [jan]
62. Chembl2146124
63. Cefuroxime Sodium [vandf]
64. Cefuroxime Sodium [mart.]
65. Dtxsid201015616
66. Hms2097o21
67. Hms3714o21
68. Cefuroxime Sodium [usp-rs]
69. Cefuroxime Sodium [who-dd]
70. Cefuroxime Sodium Salt [mi]
71. Hy-b1256
72. Mfcd09878727
73. S4620
74. Akos015961772
75. Ccg-220720
76. Cefuroxime Sodium [ep Impurity]
77. Cefuroxime Sodium [orange Book]
78. Cs-4733
79. Nsc 758166
80. Cefuroxime Sodium [ep Monograph]
81. Cefuroxime Sodium [usp Impurity]
82. Cefuroxime Sodium [usp Monograph]
83. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, Monosodium Salt (6r-(6alpha,7beta(z)))-
84. Ac-15028
85. C08108
86. D00915
87. Cefuroxime Sodium 100 Microg/ml In Acetonitrile/water
88. Cefuroxime Sodium 100 Microg/ml In Acetonitrile:water
89. Cefuroxime Sodium, European Pharmacopoeia (ep) Reference Standard
90. Cefuroxime Sodium, United States Pharmacopeia (usp) Reference Standard
91. (6r,7r)-3-(carbamoyloxymethyl)-7-[[(2z)-2-(2-furyl)-2-methoxyimino-acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
92. 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic Acid, 3-(((aminocarbonyl)oxy)methyl)-7-((2-furanyl(methoxyimino)acetyl)amino)-8-oxo-, Monosodium Salt (6r-(6.alpha.,7.beta.(z)))-
93. Sodium (6r,7r)-3-(carbamoyloxymethyl)-7-((e)-2-(furan-2-yl)-2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
| Molecular Weight | 446.4 g/mol |
|---|---|
| Molecular Formula | C16H15N4NaO8S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 8 |
| Exact Mass | 446.05082891 g/mol |
| Monoisotopic Mass | 446.05082891 g/mol |
| Topological Polar Surface Area | 202 Ų |
| Heavy Atom Count | 30 |
| Formal Charge | 0 |
| Complexity | 804 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 6 | |
|---|---|
| Drug Name | Cefuroxime and dextrose in duplex container |
| Active Ingredient | Cefuroxime sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 750mg base/vial; eq 1.5gm base/vial |
| Market Status | Prescription |
| Company | B Braun |
| 2 of 6 | |
|---|---|
| Drug Name | Cefuroxime sodium |
| Active Ingredient | Cefuroxime sodium |
| Dosage Form | Injectable |
| Route | Intramuscular, intravenous; Im-iv; Injection |
| Strength | eq 750mg base/vial; eq 7.5gm base/vial; eq 1.5gm base/vial |
| Market Status | Prescription |
| Company | Teva Pharms; Hospira; Steri Pharma; Hikma Farmaceutica |
| 3 of 6 | |
|---|---|
| Drug Name | Zinacef in plastic container |
| Drug Label | Cefuroxime is a sterile semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R, 7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2-yl)acetamido]ceph-3-em-4-carboxylate, and it has the fo... |
| Active Ingredient | Cefuroxime sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 30mg base/ml |
| Market Status | Prescription |
| Company | Covis Injectables |
| 4 of 6 | |
|---|---|
| Drug Name | Cefuroxime and dextrose in duplex container |
| Active Ingredient | Cefuroxime sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 750mg base/vial; eq 1.5gm base/vial |
| Market Status | Prescription |
| Company | B Braun |
| 5 of 6 | |
|---|---|
| Drug Name | Cefuroxime sodium |
| Active Ingredient | Cefuroxime sodium |
| Dosage Form | Injectable |
| Route | Intramuscular, intravenous; Im-iv; Injection |
| Strength | eq 750mg base/vial; eq 7.5gm base/vial; eq 1.5gm base/vial |
| Market Status | Prescription |
| Company | Teva Pharms; Hospira; Steri Pharma; Hikma Farmaceutica |
| 6 of 6 | |
|---|---|
| Drug Name | Zinacef in plastic container |
| Drug Label | Cefuroxime is a sterile semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R, 7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2-yl)acetamido]ceph-3-em-4-carboxylate, and it has the fo... |
| Active Ingredient | Cefuroxime sodium |
| Dosage Form | Injectable |
| Route | Injection |
| Strength | eq 30mg base/ml |
| Market Status | Prescription |
| Company | Covis Injectables |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - INJECTABLE;INJECTION - EQ 1.5GM BASE...DOSAGE - INJECTABLE;INJECTION - EQ 1.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50558
DOSAGE - INJECTABLE;INJECTION - EQ 7.5GM BASE...DOSAGE - INJECTABLE;INJECTION - EQ 7.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50558
DOSAGE - INJECTABLE;INTRAMUSCULAR, INTRAVENOU...DOSAGE - INJECTABLE;INTRAMUSCULAR, INTRAVENOUS - EQ 750MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 50558
DOSAGE - INJECTABLE;INJECTION - EQ 30MG BASE/...DOSAGE - INJECTABLE;INJECTION - EQ 30MG BASE/ML
USFDA APPLICATION NUMBER - 50643
Related Excipient Companies
Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Parenteral
Co-Processed Excipients
Taste Masking
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
56
PharmaCompass offers a list of Cefuroxime Sodium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cefuroxime Sodium manufacturer or Cefuroxime Sodium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cefuroxime Sodium manufacturer or Cefuroxime Sodium supplier.
PharmaCompass also assists you with knowing the Cefuroxime Sodium API Price utilized in the formulation of products. Cefuroxime Sodium API Price is not always fixed or binding as the Cefuroxime Sodium Price is obtained through a variety of data sources. The Cefuroxime Sodium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Cefuroxim Fresenius manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cefuroxim Fresenius, including repackagers and relabelers. The FDA regulates Cefuroxim Fresenius manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cefuroxim Fresenius API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cefuroxim Fresenius manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Cefuroxim Fresenius supplier is an individual or a company that provides Cefuroxim Fresenius active pharmaceutical ingredient (API) or Cefuroxim Fresenius finished formulations upon request. The Cefuroxim Fresenius suppliers may include Cefuroxim Fresenius API manufacturers, exporters, distributors and traders.
click here to find a list of Cefuroxim Fresenius suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Cefuroxim Fresenius DMF (Drug Master File) is a document detailing the whole manufacturing process of Cefuroxim Fresenius active pharmaceutical ingredient (API) in detail. Different forms of Cefuroxim Fresenius DMFs exist exist since differing nations have different regulations, such as Cefuroxim Fresenius USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cefuroxim Fresenius DMF submitted to regulatory agencies in the US is known as a USDMF. Cefuroxim Fresenius USDMF includes data on Cefuroxim Fresenius's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cefuroxim Fresenius USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cefuroxim Fresenius suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cefuroxim Fresenius Drug Master File in Korea (Cefuroxim Fresenius KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cefuroxim Fresenius. The MFDS reviews the Cefuroxim Fresenius KDMF as part of the drug registration process and uses the information provided in the Cefuroxim Fresenius KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cefuroxim Fresenius KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cefuroxim Fresenius API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cefuroxim Fresenius suppliers with KDMF on PharmaCompass.
A Cefuroxim Fresenius CEP of the European Pharmacopoeia monograph is often referred to as a Cefuroxim Fresenius Certificate of Suitability (COS). The purpose of a Cefuroxim Fresenius CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cefuroxim Fresenius EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cefuroxim Fresenius to their clients by showing that a Cefuroxim Fresenius CEP has been issued for it. The manufacturer submits a Cefuroxim Fresenius CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cefuroxim Fresenius CEP holder for the record. Additionally, the data presented in the Cefuroxim Fresenius CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cefuroxim Fresenius DMF.
A Cefuroxim Fresenius CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cefuroxim Fresenius CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cefuroxim Fresenius suppliers with CEP (COS) on PharmaCompass.
A Cefuroxim Fresenius written confirmation (Cefuroxim Fresenius WC) is an official document issued by a regulatory agency to a Cefuroxim Fresenius manufacturer, verifying that the manufacturing facility of a Cefuroxim Fresenius active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cefuroxim Fresenius APIs or Cefuroxim Fresenius finished pharmaceutical products to another nation, regulatory agencies frequently require a Cefuroxim Fresenius WC (written confirmation) as part of the regulatory process.
click here to find a list of Cefuroxim Fresenius suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cefuroxim Fresenius as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cefuroxim Fresenius API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cefuroxim Fresenius as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cefuroxim Fresenius and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cefuroxim Fresenius NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cefuroxim Fresenius suppliers with NDC on PharmaCompass.
Cefuroxim Fresenius Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cefuroxim Fresenius GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cefuroxim Fresenius GMP manufacturer or Cefuroxim Fresenius GMP API supplier for your needs.
A Cefuroxim Fresenius CoA (Certificate of Analysis) is a formal document that attests to Cefuroxim Fresenius's compliance with Cefuroxim Fresenius specifications and serves as a tool for batch-level quality control.
Cefuroxim Fresenius CoA mostly includes findings from lab analyses of a specific batch. For each Cefuroxim Fresenius CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cefuroxim Fresenius may be tested according to a variety of international standards, such as European Pharmacopoeia (Cefuroxim Fresenius EP), Cefuroxim Fresenius JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cefuroxim Fresenius USP).
